메뉴 건너뛰기




Volumn 38, Issue 14, 2002, Pages 1888-1898

Topotecan preceded by oxaliplatin using a 3 week schedule: A phase I study in advanced cancer patients

Author keywords

Malnutrition; Ovarian cancer; Oxaliplatin; Performance status; Thrombocytopenia; Topotecan

Indexed keywords

CREATININE; LACTONE; OXALIPLATIN; PLATINUM; TOPOTECAN;

EID: 0036710193     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00232-0     Document Type: Article
Times cited : (11)

References (35)
  • 1
    • 0028153260 scopus 로고
    • Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design [see comments]
    • Chou T.C., Motzer R.J., Tong Y.et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth. a rational approach to clinical protocol design [see comments] J. Natl. Cancer Inst. 86:1994;1517-1524.
    • (1994) J. Natl. Cancer Inst. , vol.86 , pp. 1517-1524
    • Chou, T.C.1    Motzer, R.J.2    Tong, Y.3
  • 3
    • 0027999967 scopus 로고
    • Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
    • Miller A.A., Hargis J.B., Lilenbaum R.C.et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors. a cancer and leukemia group B study J. Clin. Oncol. 12:1994;2743-2750.
    • (1994) J. Clin. Oncol. , vol.12 , pp. 2743-2750
    • Miller, A.A.1    Hargis, J.B.2    Lilenbaum, R.C.3
  • 4
    • 10544249871 scopus 로고    scopus 로고
    • Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence [see comments]
    • Rowinsky E.K., Kaufmann S.H., Baker S.D.et al. Sequences of topotecan and cisplatin. phase I, pharmacologic, and in vitro studies to examine sequence dependence [see comments] J. Clin. Oncol. 14:1996;3074-3084.
    • (1996) J. Clin. Oncol. , vol.14 , pp. 3074-3084
    • Rowinsky, E.K.1    Kaufmann, S.H.2    Baker, S.D.3
  • 5
    • 0030720766 scopus 로고    scopus 로고
    • Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
    • Raymond E., Burris H.A., Rowinsky E.K.et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann. Oncol. 8:1997;1003-1008.
    • (1997) Ann. Oncol. , vol.8 , pp. 1003-1008
    • Raymond, E.1    Burris, H.A.2    Rowinsky, E.K.3
  • 6
    • 0027082880 scopus 로고
    • CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
    • Masuda N., Fukuoka M., Takada M.et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol. 10:1992;1775-1780.
    • (1992) J. Clin. Oncol. , vol.10 , pp. 1775-1780
    • Masuda, N.1    Fukuoka, M.2    Takada, M.3
  • 7
    • 0035399156 scopus 로고    scopus 로고
    • Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: A phase I/II study
    • Bowman A., Rye T., Ross G.et al. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer. a phase I/II study J. Clin. Oncol. 19:2001;3255-3259.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 3255-3259
    • Bowman, A.1    Rye, T.2    Ross, G.3
  • 8
    • 0033874892 scopus 로고    scopus 로고
    • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    • de Gramont A., Figer A., Seymour M.et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2000;2938-2947.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 2938-2947
    • De Gramont, A.1    Figer, A.2    Seymour, M.3
  • 9
    • 0033989203 scopus 로고    scopus 로고
    • Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
    • Giacchetti S., Perpoint B., Zidani R.et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:2000;136-147.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 136-147
    • Giacchetti, S.1    Perpoint, B.2    Zidani, R.3
  • 10
    • 0030900145 scopus 로고    scopus 로고
    • Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comments]
    • ten Bokkel Huinink W., Gore M., Carmichael J.et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comments]. J. Clin. Oncol. 15:1997;2183-2193.
    • (1997) J. Clin. Oncol. , vol.15 , pp. 2183-2193
    • Ten Bokkel Huinink, W.1    Gore, M.2    Carmichael, J.3
  • 11
    • 0034064719 scopus 로고    scopus 로고
    • Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
    • Piccart M.J., Green J.A., Lacave A.J.et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer. a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol. 18:2000;1193-1202.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 1193-1202
    • Piccart, M.J.1    Green, J.A.2    Lacave, A.J.3
  • 12
    • 0032803291 scopus 로고    scopus 로고
    • Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin
    • Lin X., Howell S.B. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Mol. Pharmacol. 56:1999;390-395.
    • (1999) Mol. Pharmacol. , vol.56 , pp. 390-395
    • Lin, X.1    Howell, S.B.2
  • 13
    • 0033002906 scopus 로고    scopus 로고
    • Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-11) in patients with gastrointestinal tumors: Results of two independent phase I pharmacokinetic studies
    • Wasserman E., Cuvier C., Lokiec F.et al. Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-11) in patients with gastrointestinal tumors. results of two independent phase I pharmacokinetic studies J. Clin. Oncol. 17:1999;1751-1759.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 1751-1759
    • Wasserman, E.1    Cuvier, C.2    Lokiec, F.3
  • 14
    • 0033637555 scopus 로고    scopus 로고
    • Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients
    • Goldwasser F., Gross-Goupil M., Tigaud J.M.et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule. a phase I study in advanced gastrointestinal cancer patients Ann. Oncol. 11:2000;1463-1470.
    • (2000) Ann. Oncol. , vol.11 , pp. 1463-1470
    • Goldwasser, F.1    Gross-Goupil, M.2    Tigaud, J.M.3
  • 15
    • 0029034767 scopus 로고
    • High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma
    • Rosing H., Doyle E., Davies B.E.et al. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromatogr B. 668:1995;107-115.
    • (1995) J Chromatogr B , vol.668 , pp. 107-115
    • Rosing, H.1    Doyle, E.2    Davies, B.E.3
  • 16
    • 0019365237 scopus 로고
    • Reporting results of cancer treatment
    • Miller A.B., Hoogstrater B., Staquet M.et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
    • (1981) Cancer , vol.47 , pp. 207-214
    • Miller, A.B.1    Hoogstrater, B.2    Staquet, M.3
  • 17
    • 0021947525 scopus 로고
    • A pronostic inflammatory and nutritional index scoring in critically ill patients
    • Ingelbleeck Y., Carpentier Y.A. A pronostic inflammatory and nutritional index scoring in critically ill patients. Int. J. Vit. Nutr. Res. 55:1985;91-101.
    • (1985) Int. J. Vit. Nutr. Res. , vol.55 , pp. 91-101
    • Ingelbleeck, Y.1    Carpentier, Y.A.2
  • 18
    • 0020131190 scopus 로고
    • Comparison of nutritional indices and outcome of critically ill patients
    • Apelgren K., Rombeau J.L., Twomey P.L.et al. Comparison of nutritional indices and outcome of critically ill patients. Crit. Care Med. 10:1982;305-307.
    • (1982) Crit. Care Med. , vol.10 , pp. 305-307
    • Apelgren, K.1    Rombeau, J.L.2    Twomey, P.L.3
  • 19
    • 0022529253 scopus 로고
    • Use of APACHE II severity of disease classification to identify intensive-care unit patients who would not benefit from total parenteral nutrition
    • Chang R.W., Jacobs S., Lee B. Use of APACHE II severity of disease classification to identify intensive-care unit patients who would not benefit from total parenteral nutrition. Lancet. 1:1986;1483-1486.
    • (1986) Lancet , vol.1 , pp. 1483-1486
    • Chang, R.W.1    Jacobs, S.2    Lee, B.3
  • 20
    • 0030716924 scopus 로고    scopus 로고
    • Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
    • Wasserman E., Myara A., Lokiec F.et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome. two case reports Ann. Oncol. 8:1997;1049-1051.
    • (1997) Ann. Oncol. , vol.8 , pp. 1049-1051
    • Wasserman, E.1    Myara, A.2    Lokiec, F.3
  • 21
    • 0034006524 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of oxaliplatin: A critical review
    • Graham M.A., Lockwood G.F., Greenslade D.et al. Clinical pharmacokinetics of oxaliplatin. a critical review Clin Cancer Res. 6:2000;1205-1218.
    • (2000) Clin Cancer Res. , vol.6 , pp. 1205-1218
    • Graham, M.A.1    Lockwood, G.F.2    Greenslade, D.3
  • 22
    • 0028796513 scopus 로고
    • Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
    • van Warmerdam L.J., Verweij J., Schellens J.H.et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol. 35:1995;327-345.
    • (1995) Cancer Chemother. Pharmacol. , vol.35 , pp. 327-345
    • Van Warmerdam, L.J.1    Verweij, J.2    Schellens, J.H.3
  • 23
    • 15844424667 scopus 로고    scopus 로고
    • Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function
    • O'Reilly S., Rowinsky E., Slichenmyer W.et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J. Natl. Cancer Inst. 88:1996;817-824.
    • (1996) J. Natl. Cancer Inst. , vol.88 , pp. 817-824
    • O'Reilly, S.1    Rowinsky, E.2    Slichenmyer, W.3
  • 24
    • 0029966916 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of topotecan in patients with impaired renal function
    • O'Reilly S., Rowinsky E., Slichenmyer W.et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J. Clin. Oncol. 14:1996;3062-3073.
    • (1996) J. Clin. Oncol. , vol.14 , pp. 3062-3073
    • O'Reilly, S.1    Rowinsky, E.2    Slichenmyer, W.3
  • 25
    • 0026646768 scopus 로고
    • Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
    • Grochow L.B., Rowinsky E.K., Johnson R.et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos. 20:1992;706-713.
    • (1992) Drug Metab. Dispos. , vol.20 , pp. 706-713
    • Grochow, L.B.1    Rowinsky, E.K.2    Johnson, R.3
  • 26
    • 0032708102 scopus 로고    scopus 로고
    • Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel - And platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study
    • Ghamande S.A., Piver M.S. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel - and platinum-resistant recurrent ovarian or primary peritoneal cancer. a phase II pilot study J. Surg. Oncol. 72:1999;162-166.
    • (1999) J. Surg. Oncol. , vol.72 , pp. 162-166
    • Ghamande, S.A.1    Piver, M.S.2
  • 27
    • 0345059451 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
    • Herben V.M., Panday V.R., Richel D.J.et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J. Clin. Oncol. 17:1999;747-755.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 747-755
    • Herben, V.M.1    Panday, V.R.2    Richel, D.J.3
  • 28
    • 0034671437 scopus 로고    scopus 로고
    • Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
    • Hoskins P., Eisenhauer E., Vergote I.et al. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer. A National Cancer Institute of Canada Clinical Trials Group study J. Clin. Oncol. 18:2000;4038-4044.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 4038-4044
    • Hoskins, P.1    Eisenhauer, E.2    Vergote, I.3
  • 29
    • 0026652640 scopus 로고
    • Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
    • Kaye S.B., Lewis C.R., Paul J.et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 340:1992;329-333.
    • (1992) Lancet , vol.340 , pp. 329-333
    • Kaye, S.B.1    Lewis, C.R.2    Paul, J.3
  • 30
    • 0033816778 scopus 로고    scopus 로고
    • A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell ling cancer
    • Sorensen M., Jensen P.B., Herrstedt J.et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell ling cancer. Ann. Oncol. 11:2000;829-835.
    • (2000) Ann. Oncol. , vol.11 , pp. 829-835
    • Sorensen, M.1    Jensen, P.B.2    Herrstedt, J.3
  • 31
    • 0032925377 scopus 로고    scopus 로고
    • A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
    • Gerrits C.J., Schellens J.H., Burris H.et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin. Cancer Res. 5:1999;69-75.
    • (1999) Clin. Cancer Res. , vol.5 , pp. 69-75
    • Gerrits, C.J.1    Schellens, J.H.2    Burris, H.3
  • 32
    • 0033729430 scopus 로고    scopus 로고
    • Population pharmacokinetics of topotecan: Intraindividual variability in total drug
    • Montazeri A., Boucaud M., Lokiec F.et al. Population pharmacokinetics of topotecan. intraindividual variability in total drug Cancer Chemother. Pharmacol. 46:2000;375-381.
    • (2000) Cancer Chemother. Pharmacol. , vol.46 , pp. 375-381
    • Montazeri, A.1    Boucaud, M.2    Lokiec, F.3
  • 33
    • 0032999031 scopus 로고    scopus 로고
    • Cellular pharmacology of the combination of oxaliplatine with oxaliplatin in the IGROV-1 human ovarian cancer cell line
    • Goldwasser F., Bozec L., Zeghari-Squalli N., Misset J.L. Cellular pharmacology of the combination of oxaliplatine with oxaliplatin in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs. 10:1999;195-201.
    • (1999) Anticancer Drugs , vol.10 , pp. 195-201
    • Goldwasser, F.1    Bozec, L.2    Zeghari-Squalli, N.3    Misset, J.L.4
  • 34
    • 0032905667 scopus 로고    scopus 로고
    • Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 with the diaminocyclohexane platinum derivative oxaliplatin
    • Zeghari-Squalli N., Raymond E., Cvitkovic E., Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 with the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res. 5:1999;1189-1196.
    • (1999) Clin. Cancer Res. , vol.5 , pp. 1189-1196
    • Zeghari-Squalli, N.1    Raymond, E.2    Cvitkovic, E.3    Goldwasser, F.4
  • 35
    • 0032767121 scopus 로고    scopus 로고
    • Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients
    • Goldwasser F., Buthaud X., Gross M.et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anti-Cancer Drugs. 10:1999;263-265.
    • (1999) Anti-Cancer Drugs , vol.10 , pp. 263-265
    • Goldwasser, F.1    Buthaud, X.2    Gross, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.